Overview

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

Status:
COMPLETED

Trial end date:
2025-09-08

Target enrollment:

Participant gender:

Summary

The main objective of the study is to evaluate the effect on pain of a single, subcutaneous (SC) dose of LEO 158968 in participants with gout flares.

Phase:

PHASE1

Details

Lead Sponsor:

LEO Pharma